[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagogastric-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagogastric-adenocarcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631998","phase-2-tnt-with-flotdurvalumab-plus-post-op-durvalumab-for-resectable-gastroesophageal-adenocarcinoma-100631998",false,"NCT07507968","TNT With FLOT\u002FDurvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma","Total Neoadjuvant Treatment With Preoperative FLOT\u002FDurvalumab Plus Postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma","Inclusion Criteria:\n\n* Patient\\* has given written informed consent\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n* Patient is ≥ 18 years of age at time of signing the written informed consent\n* Patient has histologically proven locally advanced (cT2-4, any cN, M0 OR any cT, cN+, M0 stage) gastric, esophagogastric junction (type 1-3) or lower esophageal adenocarcinoma that is considered medically and technically resectable\n* Patient has a known PD-L1 status according to standardized TAP scoring (by local testing), any PD-L1 status is eligible\n* Patient has a ECOG performance status 0 or 1\n* Patient must have a life expectancy of at least 12 weeks\n* Patient has adequate blood count, liver-enzymes, and renal function:\n\n  1. ANC ≥ 1.0x109 cells\u002FL without the use of hematopoietic growth factors\n  2. Platelet count ≥ 75 x 109\u002FL (\\>75,000 per mm3)\\*\\*\n  3. Hemoglobin ≥ 9 g\u002FdL\\*\\*\n  4. Serum total bilirubin ≤ 1.5x institutional upper normal limit (ULN)\n  5. AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional ULN\n  6. Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.5 ULN and aPTT ≤ 1.5 ULN. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion.\n  7. Serum Creatinine ≤ 1.5 x ULN and a calculated creatinine clearance rate \\> 40 mL \u002Fmin.\n* Patient has a body weight \\> 30 kg\n* Female patients defined as women of childbearing potential (WOCBP) must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C1% per year during the treatment period and for 3 months after last dose of durvalumab or 6 months after last dose of chemotherapy, whatever is later\n* Male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use barrier contraceptive during the treatment period as well as up to 3 months after last dose of durvalumab or up to 6 months after last dose of chemotherapy, whatever is later. Male patients must refrain from donating sperm during this same period\n\nExclusion Criteria:\n\n* Patient received previous (radio)chemotherapy or checkpoint inhibition for the same condition or within the past five years for any other cancerous condition\n* Patient received prior partial or complete esophagogastric tumor resection\n* Patient has known hypersensitivity to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and\u002For any known contraindication (including hypersensitivity) to one of the study drugs\n* Patient has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Patient has lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within three months of the study enrolment, severe asthma, severe COPD, restrictive lung disease, relevant pleural effusion etc.)\n* Patient received a prior complete pneumonectomy\n* Patient has inadequate cardiac function (LVEF value \\\u003C 50 %) as determined by echocardiography\n* Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity\n* Patient received treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to stud enrollment\n* Patients has pernicious anemia or other megaloblastic anemia due to vitamin B12 deficiency\n* Patient has a medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during screening to rule out MI\n* Patient has a corrected QT interval (QTc) prolongation to \\> 470 ms (females) or \\>450 ms (males) based on average of the screening triplicate ECG\n* Patient has a history of malignancy other than EGA except for:\n\n  1. Malignancy treated with curative intent and cured with no known active disease ≥ 3 years before the first dose of study treatment and of low potential risk for recurrence.\n  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  3. Adequately treated carcinoma in situ without evidence of disease\n* Patient has an uncontrolled infection requiring IV antibiotics, antivirals or antifungals within 14 days prior to enrolment\n* Patient has active HBV infection, which is characterized by positive HBV surface antigen (HBsAg) and\u002For positive HBc antibodies (anti-HBcAb) with detectable HBV DNA (≥ 10 IU\u002FmL or above the limit of detection per local laboratory standard), unless the participant is treated with antiviral therapy, as per institutional practice. The HBV antiviral therapy must be initiated prior to randomization, and participants must remain on antiviral therapy for the study duration and for 6 months after the last dose of response (e.g., reduction HBV DNA levels) prior to starting intervention.\n\nNote: Patients who test positive for HBsAg or anti-HBc with undetectable HBV DNA (\\\u003C 10 IU\u002FmL or under the limit of detection per local laboratory standard) do not require antiviral therapy prior to enrollment. These patients are eligible and will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (≥ 10 IU\u002FmL or above the limit of detection per local laboratory standard). The HBV DNA detectable patients must initiate and remain on antiviral therapy for the trial duration and for 6 months after the last dose of durvalumab\n\n* Patient has active HCV infection (as characterized by the presence of detectable HCV RNA and anti-HCV antibody \\[anti-HCV\\]) unless the patient is managed per local institutional practice for the trial and for 6 months after the last dose of durvalumab\n* Patient has any co-infection with HBV and HDV (HDV-positive infection is indicated by the presence of anti-HDV antibodies)\n* Patient has active tuberculosis infection (clinical evaluation that may include clinical history, physical examination, and radiographic findings, or tuberculosis testing in line with local practice)\n* Patient has known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled:\n\n  1. Undetectable viral RNA\n  2. CD4+ count ≥ 350 cells\u002Fmm3\n  3. No history of acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).\n\nIf an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Patient must be tested for HIV if acceptable by local regulations or an institutional IRB\u002FIEC.\n\n* Patient has active or history of autoimmune disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following are exceptions to this criterion:\n\n  1. Patients with vitiligo or alopecia\n  2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n  3. Any chronic skin condition that does not require systemic therapy\n  4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n  5. Patients with celiac disease controlled by diet alone\n* Patient currently or priorly used immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n  1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n  2. Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n  3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* Patient received live, attenuated vaccine within 30 days prior initiation of study drug\n* Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect\n* Patient participated in another interventional clinical study within 28 days prior to study enrollment or participation in a clinical study at the same time as this study, unless it is an observational\u002F non-interventional study or during the follow-up period of an interventional study\n* Patient has taken an investigational drug within 28 days prior to initiation of study drug\n* Female patients, who are pregnant or breast feeding or planning to become pregnant within 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment","ALL","18 Years",{"count":19,"type":20},101,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradigms, builds directly on the strong clinical signal from the MATTERHORN trial, and offers a rational, biologically sound framework for future therapy intensification and innovation.\n\nBy moving systemic therapy entirely into the preoperative phase, we aim to:\n\n* Improve patient outcomes through better adherence and deeper response\n* Minimize postoperative therapy-related dropout\n* Create a platform for rational post-surgical drug testing and individualized treatment escalation The trial will provide pivotal evidence to guide the next generation of curative-intent treatment strategies for EGA.",[26],"Esophagogastric Adenocarcinoma",[28,29,30,31,32],"neoadjuvant","gastric","esophageal","Durvalumab","FLOT chemotherapy","NOT_YET_RECRUITING","2026-03-30",{"date":36,"type":37},"2026-04-02","ACTUAL",{"date":39,"type":20},"2026-07-01",{"date":41,"type":20},"2030-02-01",{"name":43,"class":44},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","OTHER",29,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100563994","phase-1-a-study-of-mesothelin-targeted-car-t-cell-therapy-in-people-with-esophagogastric-cancer-100563994","NCT06623396","A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer","A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T-Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis","Inclusion Criteria:\n\n* Aged ≥18 years\n* Diagnosis of pathologically confirmed EG adenocarcinoma\n* Diagnosis of metastatic or recurrent disease\n* ECOG performance status of 0-1\n* Life expectancy of ≥4 months\n\nInclusion Criteria for Leukapheresis:\n\n* Written informed consent for the study (from participant)\n* Life expectancy of ≥4 months\n* ECOG performance status of 0-1\n* Histologic diagnosis that \\& \\>25% of the tumor expresses MSLN by IHC analysis. Archival tissue obtained up to 2 years before study enrollment is acceptable. IHC testing of a cell block from cytology (e.g., ascitic fluid) is acceptable if approved by the study pathologist. If adequate archival tissue is not available at screening, a fresh tumor biopsy should be obtained\n* Stage IV disease with gross peritoneal carcinomatosis on imaging and\u002For microscopic peritoneal involvement by cytology or noted during diagnostic laparoscopy\n* Disease progression or treatment intolerance after receiving at least 1 treatment regimen in the metastatic setting; patients with disease recurrence within 6 months of completing curative systemic therapy (chemotherapy, chemoradiation or adjuvant immunotherapy) are also eligible\n* Patients with Her2 positive disease must have received ≥1 line of anti-Her2 based therapy\n* At least 1 measurable or evaluable lesion per RECIST 1.1. Screening imaging must be obtained within 6 weeks of signing the informed consent form\n* Completion of systemic therapy at least 7 days before leukapheresis\n\n  o Immune checkpoint inhibitor therapy must be completed at least 14 days before leukapheresis\n* Lab requirements (hematology):\n\n  * Absolute neutrophil count ≥1.0 K\u002FmcL\n  * Hemoglobin ≥9 gm\u002FdL\n  * Platelet count ≥75 K\u002FmcL\n  * Blood product transfusion or growth factor support cannot occur within 7 days of testing\n* Lab requirements (serum chemistry):\n\n  * Bilirubin ≤1.5× upper limit of normal (ULN)\n  * Serum alanine aminotransferase and serum aspartate aminotransferase (ALT\u002FAST) level ≤3× ULN\n  * Calculated clearance of ≥50 mL\u002Fmin by Cockcroft-Gault equation\n* Negative screen for infectious disease markers, including hepatitis B core antibody, hepatitis B surface antigen, hepatitis C antibody, HIV 1-2 antibody, HTLV antibody and syphilis antibody\n\n  o Note: Patients with a history of hepatitis B virus infection are eligible if the hepatitis B viral load is undetectable. Patients with a history of hepatitis C virus infection who were treated for hepatitis C and cured are eligible if the hepatitis C viral load is undetectable\n* Serum pregnancy test with negative result at screening and preconditioning and must be willing to use effective and reliable contraception for at least 12 months after T cell infusion (for female participants of childbearing age)\n* Resolution of all acute toxic effects of any previous therapeutic or palliative chemotherapy, radiotherapy, or surgical procedures to grade ≤1 (CTCAE v5.0), except for neuropathy and alopecia\n\nInclusion Criteria for lymphodepleting chemotherapy\u002FCAR T cell infusion\n\n* Life expectancy of ≥4 months\n* ECOG performance status of 0-1\n* At least 1 measurable or evaluable lesion per RECIST 1.1. Screening imaging must be obtained within 4 weeks before the date of lymphodepletion\n* Completion of systemic therapy at least 14 days before lymphodepleting chemotherapy\n\n  o Immune checkpoint inhibitor therapy must be completed at least 28 days before lymphodepleting chemotherapy\n* Lab requirements (hematology):\n\n  * Absolute neutrophil count ≥1.5 K\u002FmcL\n  * Hemoglobin ≥8 gm\u002FdL\n  * Platelet count ≥75 K\u002FmcL\n* Lab requirements (serum chemistry):\n\n  * Bilirubin ≤1.5× upper limit of normal (ULN)\n  * Serum alanine aminotransferase and serum aspartate aminotransferase (ALT\u002FAST) level ≤3× ULN\n  * Calculated clearance of ≥50 mL\u002Fmin by Cockcroft-Gault equation\n* Serum pregnancy test with negative result within 7 days of planned lymphodepletion date and must be willing to use effective and reliable contraception for at least 12 months after T cell infusion (for female participants of childbearing age)\n* Resolution of all acute toxic effects of any previous therapeutic or palliative chemotherapy, radiotherapy, or surgical procedures to grade ≤1 (CTCAE v5.0), except for neuropathy and alopecia\n\nParticipant Exclusion Criteria\n\nExclusion Criteria for Leukapheresis or Lymphodepleting chemotherapy\u002FCAR T cell infusion: Participants are excluded from enrollment if any of the following criteria apply:\n\n* Pregnant or lactating\n* HIV, active hepatitis C virus, or active hepatitis B virus infection, as determined by quantitative PCR (patients who have undergone negative testing prior to leukapheresis do not require repeat testing)\n* Receiving therapy for concurrent active malignancy\n\n  * Note: Patients receiving treatment for in situ skin malignancies are not excluded.\n  * Patients with any malignancy diagnosed \\>3 years before that is thought to be curatively treated and\u002For has a low risk of recurrence are eligible. Patients may continue to receive adjuvant therapy at the time of study enrollment (e.g., adjuvant hormonal therapy for curatively treated breast cancer).\n* Known hematologic malignancy requiring treatment in the preceding 5 years or a known history of lymphoid malignancy\n* Previous receipt of CAR T cell therapy or any other cellular therapy\n* Previous mesothelin-directed therapy Any major abdominal surgery (laparotomy with resection of gastrointestinal tract or organ resection) that is completed \\<28 days before study enrollment. Patients who have undergone diagnostic laparoscopy can be included in the study without regard to timing\n* Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible if all of the following criteria are met:\n\n  * Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study\n  * Completion of radiotherapy ≥4 weeks before the screening radiographic study\n* Active autoimmune disease that has required systemic treatment within 1 year before leukapheresis (with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)\n\n  o Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Receiving daily systemic corticosteroids ≥10 mg of prednisone daily or equivalent or receiving immunosuppressive or immunomodulatory treatment\n* Any of the following cardiac conditions:\n\n  * New York Heart Association stage III or IV congestive heart failure\n  * Myocardial infarction ≤6 months before enrollment\n  * History of myocarditis\n  * Serious uncontrolled cardiac arrhythmia, unstable angina, or uncontrolled infection\n  * Left ventricular ejection fraction ≤40%\n* Active interstitial lung disease\u002Fpneumonitis or a history of interstitial lung disease\u002Fpneumonitis requiring treatment with systemic steroids\n* Baseline pulse oximetry \\<90% on room air at the screening time point\n* Known active infection requiring antibiotic treatment 7 days before leukapheresis\n\n  o Note: Treatment can be delayed at the discretion of the treating physician to allow the patient to recover from the infection.\n* Any other medical condition, e.g. fever \\>38.0 degrees C, that, in the opinion of the PI, may interfere with the subject's participation in or compliance with the study\n* Receipt of live, attenuated vaccine within 8 weeks before the planned lymphodepleting chemotherapy date\n* Deemed to be noncompliant by the study team for administration of a high-risk treatment agent and for close follow-up after treatment as required by the protocol",{"count":54,"type":20},18,[56],"PHASE1","Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.",[59,60,61,62,26,63,64,65],"Mesothelin Positive","Mesothelin-Expressing Tumors","Esophageal Adenocarcinoma","Esophageal Adenocarcinomas","Peritoneal Carcinomatosis","Breast Neoplasms","Diabetes Mellitus",[67,68,69,70,71,72,73,74],"mesothelin positive","mesothelin-expressing tumors","esophageal adenocarcinoma","esophageal adenocarcinomas","esophagastric adenocarcinoma","peritoneal carcinomatosis","CAR T-Cell Therapy","24-214","RECRUITING","2026-02-09",{"date":78,"type":37},"2026-02-11",{"date":80,"type":37},"2024-09-30",{"date":82,"type":20},"2028-09-30",{"name":84,"class":44},"Memorial Sloan Kettering Cancer Center",7,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100379327","molecular-characteristics-of-gastroesophageal-adenocarcinoma-mocha-a-prospective-feasibility-study-100379327","NCT04219137","Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study","MOCHA","Inclusion Criteria:\n\nArm 1:\n\n* Patients with suspected or histologically confirmed localized gastroesophageal adenocarcinoma amenable to curative intent therapy with surgery as standard of care, either with or without induction chemotherapy or chemo radiotherapy.\n* Age ≥18 years.\n* Eastern Cooperative Group (ECOG) performance status 0-2\n\nArm 2\n\n* Patients must have a histological or radiological diagnosis of advanced gastroesophageal cancer.\n* Patient must have a tumour lesion that is amenable to a core needle biopsy as judged by a staff radiologist. A minimum of 3 x 18G good quality tumour cores must be safely obtainable under CT or US guidance. Biopsy to be completed before systemic therapy begins.\n* Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied. See Section 13.1.3 for the evaluation of measurable disease. Patients with locally advanced gastroesophageal cancer with no metastatic disease who are not candidates for curative intent therapy as per part 1 of the protocol, are eligible for part 2 and are exempt from this criterion.\n* Patients must be fit enough to safely undergo a tumour biopsy as judged by the investigator.\n* Age ≥ 18 years.\n* Eastern Cooperative Group (ECOG) performance status 0-2\n* Life expectancy of greater than 90 days, as judged by the investigator.\n* Patients plan to undergo systemic treatment with platinum-based chemotherapy (e.g. FOLFOX, CF, CX with or without Herceptin) as first line standard systemic palliative treatment, or as part of a first line clinical trial.\n* Within 14 days of the proposed biopsy date, patients must have normal organ and marrow functions.\n\nExclusion Criteria:\n\nArm 1\n\n* Patients who are planned for definitive chemoradiation without surgical resection will be excluded from this study.\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n\nArm 2\n\n* Patients with one or more contraindications to tumour biopsy according to UHN's standard biopsy procedures.\n* Patients who had prior systemic treatment for advanced or metastatic gastroesophageal cancer.\n* Patients who are currently on anti-cancer treatment including chemotherapy for another malignancy.\n* Patients with known brain metastases are excluded from participation in this clinical study.\n* Patients with advanced gastroesophageal cancer who are going to be treated with non-platinum based chemotherapy in the first line setting.\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any condition that would, in the investigators' judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.",{"count":94,"type":20},120,"OBSERVATIONAL","Researchers are looking to further our knowledge on disease biology and treatment selection for gastroesophageal adenocarcinoma. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients for the future.",[26],"2025-05-13",{"date":100,"type":37},"2025-05-14",{"date":102,"type":37},"2019-11-14",{"date":104,"type":20},"2027-11",{"name":106,"class":44},"University Health Network, Toronto",1]